Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Nikolay Novitski: A New Era in Cardiovascular Prevention
Nikolay Novitski/LinkedIn
May 5, 2026, 16:28

Nikolay Novitski: A New Era in Cardiovascular Prevention

Nikolay Novitski, Deputy chief physician, Associate professor Kaluga university, Board member Russian HF society, shared a post on X:

”Lipoprotein(a), or Lp(a), is an important cardiovascular risk factor that is largely unaffected by lifestyle changes or statin therapy.

Emerging therapies include:

  • Pela (ASO) – approximately an 80 percent reduction (expected in 2026)
  • Olpa (siRNA) – approximately a 71 to 101 percent reduction (expected in 2026)
  • Lepo (siRNA) – approximately a 94 percent reduction, with effects lasting up to 1.5 years after a single injection
  • Muva (oral) – approximately an 86 percent reduction in Lp(a)

Important note:

  • Very low Lp(a) levels may be associated with an increased risk of type 2 diabetes.”

Nikolay Novitski: A New Era in Cardiovascular Prevention

Stay updated with Hemostasis Today.

Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today Medicine Nikolay Novitski
NewsFeed